David Beale PhD Supplementary Scholarship in Prostate Cancer Research - South Australian immunoGENomics Cancer Institute (SAiGENCI)

The David Beale PhD Supplementary Scholarship in Prostate Cancer Research was established in 2023 from a generous donation to the University from David Beale to support a full-time PhD or MPhil student who is commencing or undertaking research in better understanding the causes and exploring potential treatments and cures for prostate cancer.

Eligibility:

Applicants must be Australian citizens, permanent residents of Australia, or international students who are acceptable as candidates for a PhD or MPhil degree at the University of Adelaide.

To be eligible for the scholarship, applicants must:

• Be enrolled full time in a PhD or MPhil with SAiGENCI at The University of Adelaide,
• Be undertaking research into prostate cancer,
• Be a recipient of a major scholarship (e.g. Research Training Program Scholarship, University of Adelaide Research Scholarship or equivalent major scholarship),
• Not currently receive a supplementary scholarship (or agrees to relinquish supplementary scholarship if successful), and
• Agree to provide the scholarship donor with annual progress reports and a brief update every 6 months.

Stipend:

The scholarship will be for up to 3.5 years and has a stipend of $10,000 per annum. It is likely to be tax exempt, subject to Taxation Office approval.  In addition, the awardee will be resourced with up to $5,000 in their second year to support travel to a relevant conference, workshop or laboratory visit, or other research project costs.  

Enquiries:

Joanna Sundstrom
South Australian immunoGENomics Cancer Institute
Tel: (08) 8128 4218
Email: [email protected]

Applications:

To apply send the following documents to Joanna Sundstrom ([email protected] ) with the name of scholarship in the subject heading:

• CV
• Academic transcript
• Expression of interest outlining the nature of their research and how it will meet the scholarships objectives in better understanding the causes of prostate cancer and exploring potential treatments (maximum 500 words)
• Statement on how the award would benefit the applicant (maximum 250 words)

Applications should be submitted no later than Wednesday 31 January 2024.